Status:

UNKNOWN

AST-021p Study in Advanced Solid Tumors

Lead Sponsor:

Aston Sci. Inc.

Conditions:

Advanced Cancer

Eligibility:

All Genders

19+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the safety, tolerability and optimal Immunogenic dose of therapeutic cancer vaccine (AST-021p) in patients With advanced solid tumors A phase 1 study

Detailed Description

Recurrent or advanced solid cancer patients without applicable standard treatments will be included in the 4 dose groups (4 cohort groups- 1.2mg, 2.4mg,3.6mg and 4.8mg) of AST-021p. Participants in ea...

Eligibility Criteria

Inclusion

  • has recurrent or metastatic solid cancer that has been proven histologically or cytologically and cannot be treated with surgery or radiotherapy for the purpos of complete remission
  • does not have a standard treatment that can be applied clinically according to the investigator's judgment
  • has an expected life expectancy of more than 3 months
  • adults aged 19 or older based on screening day
  • ECOG performance status : 0\~1

Exclusion

  • Has a history of hypersensitivity or other contraindications to rhGM-CSF and Montanide ISA 51 VG
  • Has a history of other primary malignant tumor
  • Has autoimmune diseases or inflammatory diseases
  • Has a history of active primary immunodeficiency disease
  • Has active infection including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
  • Is pregnant or breastfeeding or expecting to conceive children
  • has a history of immune suppression therapy ≤4 weeks prior to the screening day

Key Trial Info

Start Date :

June 9 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2023

Estimated Enrollment :

19 Patients enrolled

Trial Details

Trial ID

NCT04864418

Start Date

June 9 2021

End Date

November 1 2023

Last Update

July 20 2023

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Korea University Anam Hospital

Seoul, South Korea

2

Korea University Guro Hospital

Seoul, South Korea

3

Seoul ST. Mary's Hospital

Seoul, South Korea

AST-021p Study in Advanced Solid Tumors | DecenTrialz